Cargando…

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression

Detalles Bibliográficos
Autores principales:	Okada, Yosuke, Sone, Takehiro, Takada, Kohei, Ogata, Hiraku, Saito, Keita, Kimura, Fumihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Haematology Images
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175818/ https://www.ncbi.nlm.nih.gov/pubmed/35846216 http://dx.doi.org/10.1002/jha2.364

Ejemplares similares

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
por: Zhang, Man, et al.
Publicado: (2023)

Images in haematology: Primary cutaneous diffuse large B cell lymphoma, leg type with an unusual presentation: A diagnostic challenge
por: Villagrasa‐Boli, Pablo, et al.
Publicado: (2023)

Investigating the response of paediatric leukaemia‐propagating cells to BCL‐2 inhibitors
por: Diamanti, Paraskevi, et al.
Publicado: (2020)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions
por: Protrka, Z., et al.
Publicado: (2011)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

MYC amplification in leukemia detected by cytogenetics
por: Safranauskas, Roberta Maria da Silva Oliveira, et al.
Publicado: (2021)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

In situ diffuse large B‐cell lymphoma in haemorrhoidectomy tissue
por: Nakai, Osamu, et al.
Publicado: (2022)

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction
por: Mitobe, Masaki, et al.
Publicado: (2021)

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2014)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Overexpression of Bcl2 in Osteoblasts Inhibits Osteoblast Differentiation and Induces Osteocyte Apoptosis
por: Moriishi, Takeshi, et al.
Publicado: (2011)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Correction: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Publicado: (2014)

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2018)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
por: Li, Lu, et al.
Publicado: (2018)

Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type
por: Wang, Jing-hua, et al.
Publicado: (2017)

Immunohistochemistry for c‐myc and bcl‐2 overexpression improves risk stratification in primary central nervous system lymphoma
por: Hatzl, Stefan, et al.
Publicado: (2020)

Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients
por: Ting, Choo-Yuen, et al.
Publicado: (2019)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma
por: Ali, Seemal, et al.
Publicado: (2022)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

Primary cutaneous T‐follicular helper lymphoma
por: Fenu, Elena M., et al.
Publicado: (2023)

C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in OSCC
por: Chen, Xiyan, et al.
Publicado: (2017)

Hydroxycarbamide‐related cutaneous ulcer complicated by osteomyelitis
por: England, James T., et al.
Publicado: (2021)

Hyper‐intense lesion in the pons on brain magnetic resonance imaging in a patient with diffuse large B‐cell lymphoma
por: Saito, Yo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_21r97ilrdpop02pb4rpsmiomms